Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP0042 in Advanced Leukemias
2024-514588-24-00Phase 2Suspended
- Sponsor
- Ellipses Pharma
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of ep0042 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (2 arms), sponsored by Ellipses Pharma. Primary endpoints: Incidence of dose-limiting toxicities (DLTs) - Module 1, Incidence of adverse events (AEs) and serious adverse events (SAEs) - Module 1 and 4 more. Started Aug 2024; status: suspended.
02
Drugs
ep0042
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2024-514588-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514588-24-00.